BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Report Third Quarter 2025 Financial Results on November 3

BioCryst to Report Third Quarter 2025 Financial Results on November 3

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at .

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on .

BCRXW

Contact:

Investors:

Media:



EN
20/10/2025

Underlying

BCRXBioCryst Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
KURA KURA ONCOLOGY INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
SRRK SCHOLAR ROCK HOLDING CORPORATION
NUVB NUVATION BIO INC (A)
TNGX TANGO THERAPEUTICS
INC
14h / 12m 14h / 12m 1 EN
Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip
BCRX BIOCRYST PHARMACEUTICALS INC.
02/27/26 February 27, 2026 1 EN
 PRESS RELEASE
Free
BCRX BioCryst Pharma...

BioCryst Reports Full Year 2025 Financial Results and Provides Busines...

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)— —Record GAAP and non-GAAP operating profit for full year 2025— —Maintained full year 2026 ORLADEYO revenue guidance between $625 and $645 million— —Received FDA approval for ORLADEYO oral pellets for patients with HAE Aged 2 to

February 26, 2026 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
OCUP REVOLUTION MEDICINES
DAWN OCUPHIRE PHARMA INC
STX DAY ONE BIOPHARMACEUTICALS INC
GLUE SEAGATE TECHNOLOGY HLDGS PLC
GFS MONTE ROSA THERAPEUTICS INC
MLTX GLOBALFOUNDRIES INC
EWTX MOONLAKE IMMUNOTHERAPEUTICS
QBTS EDGEWISE THERAPEUTICS INC
IONQ D-WAVE QUANTUM INC.
DBD IONQ INC
BCAX DIEBOLD NIXDORF INCORPORATED
BICARA THERAPEUTICS INC.
02/23/26 February 23, 2026 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
SRPT Sarepta Therape...
NVCR NOVOCURE LTD. ... (+20)

The Week Ahead in Life Sciences

Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent

SRPT SAREPTA THERAPEUTICS INC.
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
GERN GERON CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
WVE WAVE LIFE SCIENCES
UTHR UNITED THERAPEUTICS CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
OCUP OCUPHIRE PHARMA INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GLUE MONTE ROSA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
02/23/26 February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch